14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
IMDX vs PSNL: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas PSNL carries 43.3/100 (HOLD) at $14.72 (N/M Forward P/E, -156.7% operating margin).
Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. PSNL 43.3/100 HOLD), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. -1883.2% operating margin) and revenue trajectory (+76.6% vs. +115.0% YoY).
Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile PSNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Diagnostics & Research value chain with $1.6B market capitalization and -156.7% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ IMDX vs PSNL Key Questions & Quantitative Answers
As of Nov 19, 2026, Personalis, Inc. (PSNL) is the stronger overall head-to-head candidate over Insight Molecular Diagnostics Inc. (IMDX) in the Tradestie Institutional Equity Comparison Engine, winning 5–3 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Options & Positioning). IMDX carries a Unified Composite Score of 45.5/100 (HOLD) at $1.66 (N/M Forward P/E, -1883.2% operating margin), whereas PSNL carries 43.3/100 (HOLD) at $14.72 (N/M Forward P/E, -156.7% operating margin). Composite vs. Pillar Nuance: While IMDX currently prints a higher short-term Unified Composite Score (45.5/100 HOLD vs. PSNL 43.3/100 HOLD), PSNL captures the overall institutional head-to-head verdict (5–3 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (-156.7% vs. -1883.2% operating margin) and revenue trajectory (+76.6% vs. +115.0% YoY). Technical & Structure Timing Caution: IMDX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 21.9); meanwhile PSNL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
PSNL leads the Growth & Scale pillar: IMDX posts +115.0% YoY revenue growth and +0.0% YoY earnings growth on $2.0M TTM revenue (55.6% gross margin, -1883.2% operating margin), compared with PSNL at +76.6% YoY revenue growth and +0.0% YoY earnings growth on $81M TTM revenue (16.7% gross margin, -156.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IMDX cumulative revenue shifted N/A while PSNL shifted +75.0%. In operating R&D and SG&A reinvestment, IMDX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for PSNL.
IMDX screens cheaper on headline valuation multiples. IMDX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 18.8x EV/Revenue (unreported FCF margin), whereas PSNL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 19.3x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMDX (-23603.1% ROE) versus PSNL (-62.1% ROE) capital efficiency.
In options market volatility and institutional positioning, IMDX carries 99.4% implied volatility (12th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.91β · 76% Vol realized risk). By comparison, PSNL carries 32.9% implied volatility (2nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.69β · 23% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.